Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ticagrelor · 1 trial · 1 indication
Platelet inhibition evaluated with the VASP assay 45 days after myocardial infarction.
| Arm | Type | Description |
|---|---|---|
| Standard ticagrelor maintenance dose | ACTIVE_COMPARATOR | Ticagrelor 90 mg twice daily for the first 45 days after myocardial infarction treated with percutaneous coronary intervention. |
| Reduced ticagrelor maintenance dose | EXPERIMENTAL | Ticagrelor 90 mg twice daily for the first 30 days after myocardial infarction treated with percutaneous coronary intervention, then reduction of the maintenance dose to ticagrelor 60 mg twice daily for the next 15 days. |
| Name | Type | Description |
|---|---|---|
| Ticagrelor 90 mg | DRUG | Ticagrelor 90 mg twice daily |
| Ticagrelor 60 mg | DRUG | Ticagrelor 60 mg daily |
Inclusion Criteria: * provision of informed consent prior to any study specific procedures * diagnosis of acute ST-segment elevation myocardial infarction or acute non-ST-segment elevation myocardial infarction according to the Third Universal Definition of Myocardial Infarction * index event treat...
Ticagrelor is a small molecule being studied for use in patients who have had a myocardial infarction, commonly known as a heart attack. It is being investigated as a treatment to be given early after the event, with the goal of improving outcomes in this patient population.
Ticagrelor is being developed by Collegium Pharmaceutical, Inc., a company traded on the stock exchange under the ticker symbol COLL. The company is conducting clinical research to evaluate the drug's effectiveness in patients who have experienced a myocardial infarction.
Ticagrelor is currently in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 3 trial is a pilot study that has been completed, and the drug is still being evaluated for its potential use in myocardial infarction.
Ticagrelor has one completed Phase 3 clinical trial with the identifier NCT03251859, titled "Effectiveness of Lower Maintenance Dose of Ticagrelor Early After Myocardial Infarction (ELECTRA) Pilot Study." This trial enrolled 52 participants in Poland and was an active-controlled, randomized study.
Ticagrelor is the generic name of the drug being developed by Collegium Pharmaceutical. It is not known by any other alternative names in the context of this development program. The drug is being studied specifically for its use in patients with myocardial infarction.